Telix Pharmaceuticals Limited American
Telix Pharmaceuticals Limited American Depositary Shares is a depositary share security representing ordinary shares of Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals. The company develops and commercializes products across oncology and precision medicine, with an emphasis on targeted radioactive medicines used in cancer care and medical imaging. Its current business spans therapeutics, precision medicine, and manufacturing solutions, supporting the discovery, production, and delivery of radiopharmaceutical products and related technologies. Telix Pharmaceuticals Limited also works with healthcare providers, hospitals, and research partners in markets that rely on specialized nuclear medicine and molecular imaging tools. As an American Depositary Share, it provides U.S. investors with a U.S.-traded form of exposure to the company’s ordinary shares while the underlying business remains centered on its biopharmaceutical operations.
$10.69
+$0.12 (+1.14%)
EOD Oct 16, 2026
Operating margin is thin at 2.25%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 55.6%, still solid. Margins contracted 8.5pp, which offsets some of the top-line progress.
Free cash flow declined 1251% versus the prior year, cash generation momentum has weakened. ROIC dropped from 11.93% to 1.79%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$804M
▲ +55.6% YoY
Net Income (TTM)
-$7M
▼ -121.2% YoY
Op. Margin
2.25%
▼ -8.5pp YoY
ROIC
1.79%
▼ -10.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$61M
▼ -1250.9% YoY
Op. Cash Flow (TTM)
-$61M
▼ -1250.9% YoY
Net Debt
$325M
Cash & Equiv.
$142M
3Y CAGR: +94.7%
Continue Research
Is Telix Pharmaceuticals Limited American (TLX) overvalued?
Telix Pharmaceuticals Limited American (TLX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Telix Pharmaceuticals Limited American scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Telix Pharmaceuticals Limited American a high-quality business?+
Telix Pharmaceuticals Limited American scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.2% operating margin and a 1.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Telix Pharmaceuticals Limited American a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh TLX's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.